Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Obducat launch upgraded capabilities for the EITRE® NIL product range to meet needs from emerging markets

OBDUCAT AB (publ) subsidiary Obducat Technologies AB, a leading supplier of lithography solutions based on nanoimprint lithography (NIL), announce the integration of new UV modules for the EITRE[®] product range. The new UV modules make it possible for customers to configure the Eitre tools with ultra-high UV light intensity.The continuous development and introduction of novel imprint materials create the market need for more versatile and configurable R&D tools that can be adapted to specific customer requirements. The development of new imprint materials is driven, to a large extent,

2020 Bulkers Ltd. (2020) – Commercial update and key information relating to the cash distribution for December 2020

Hamilton, Bermuda, January 12, 2021 Commercial update: In December 2020, the Company achieved average time charter equivalent earnings of approximately US$20,300 per day, gross. The Company’s three vessels trading on index-linked time charter earned approximately US$21,400 per day, gross, including average daily scrubber benefits of approximately US$1,600 per day. The Company’s five vessels trading on fixed time charter earned approximately US$19,700 per day, gross, including average daily scrubber benefits of approximately US$1,200 per day for three of the vessels. The Baltic 5TC

Adverty is granted second US patent for in-game ad viewability technology

Adverty AB (publ) has been granted a second patent by the United States Patent and Trademark Office for its in-game ad viewability technology. The new technical patent protects a method of determining whether an advert is considered visible in a three-dimensional gaming environment rendered on a screen - a key functionality of Adverty’s industry-leading in-game advertising platform.Adverty, the leading in-game platform for advertisers, agencies and game developers, today announces the notice of allowance for its most recent in-game ad viewability technology patent by the United States

HKScan aiming at carbon-neutral food production

HKScan has set the goal of carbon neutrality of its own industrial production by the end of 2025 and carbon neutrality of the entire food chain from farms to consumers by the end of 2040 at the latest. Climate work is carried out in all our home market areas in Finland, Sweden, the Baltics and Denmark. Achieving the targets requires both a significant reduction of emissions and an increase in carbon sinks together with contract farmers and other partners. This work is led in line with the company's own Zero Carbon climate plan.HKScan Corporation, Press Release, 12 January 2021 The Zero

TePe Interdental Brushes – a sustainable choice for healthier mouths

Reducing the carbon footprint by 80% – without compromising on product quality, efficiency or design. TePe now offers consumers the opportunity to make a conscious choice by introducing a more sustainable interdental brush.‘Taking care of your mouth throughout life will benefit your overall health and well-being. Thus, the aim of our products and solutions is to enable a long-term healthy lifestyle. Helping our customers make informed choices without having to compromise on quality or functionality is key in our journey towards a more sustainable range', says Helena Ossmer Thedius,

Sweco acquires the Finnish engineering and architecture consultancy Optiplan

Sweco has signed an agreement with the construction company NCC Suomi Oy to acquire Optiplan Oy with approximately 150 employees. The acquisition strengthens Sweco’s expertise in the area of designing sustainable and energy efficient residential and non-residential buildings.“I am very pleased that Optiplan will join Sweco and further strengthen our position in sustainable building design and architecture in Finland, and I would like to welcome our new colleagues to Sweco”, says Åsa Bergman President and CEO of Sweco. Optiplan has approximately 150 experts in four cities: Helsinki,

Read original

Elisa acquires camLine Group

ELISA CORPORATION INVESTOR NEWS RELEASE 12 JANUARY 2021 AT 9:00 AMElisa and camLine Holding AG have signed and closed an agreement in which Elisa acquires 100 per cent of camLine GmbH shares. German based camLine is a software solution provider for manufacturing industry with strong focus on manufacturing execution systems (MES), quality and operational excellence. The company has a global customer base, including semiconductor and electronics manufacturers, and medical devices. The transaction is consistent with Elisa’s strategy to grow digital businesses internationally and it

IRRAS Announces Collaboration with Karolinska University Hospital

· Collaboration agreement with Neurosurgery Department of Karolinska University Hospital will further enhance the usage of the company’s transformative IRRAflow system to benefit neurocritical care patients in Sweden · Karolinska University Hospital is one of Scandinavia’s premier health facilities and one of Europe’s largest teaching hospitalsStockholm, January 12, 2021 – IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced a collaboration agreement with Karolinska University Hospital, a

NCC sells its Finnish design and engineering business Optiplan to Sweco

NCC sells its subsidiary Optiplan, the design and engineering company, to Sweco. Optiplan offers design and engineering services to the construction industry in Finland. The divestment is expected to have a positive earnings effect of approximately SEK 40 M in the business area Building Nordics in the fourth quarter 2020.Optiplan is a design and engineering company with approximately 150 employees and annual net sales of about 13 million EUR operating solely on the Finnish market, providing services to NCC and other construction companies. The majority of its revenue comes from outside of

Q1: Strong organic growth and earnings trend mark beginning of the year

First quarter •    Net sales rose 5.3 per cent to SEK 3,696 million (3,508). •    Organic sales growth was 8.0 per cent (6.1), of which SMB accounted for 7.1 per cent (0.3), LCP for 8.2 per cent (15.1) and B2C for 16.0 per cent (neg: 23.4). •    The gross margin amounted to 15.6 per cent (16.0). •    Adjusted EBITA amounted to SEK 171 million (156), corresponding to an adjusted EBITA margin of 4.6 per cent (4.5). •    EBIT totalled SEK 132 million (118), including items affecting comparability of a negative SEK 14 million (neg: 14). •    Profit for the quarter was SEK 90

Kemira upgrades its 2020 outlook

Kemira Oyj, Inside information, January 12, 2021 at 9.00 am (EET)Kemira upgrades its 2020 outlook Kemira upgrades its 2020 outlook following good demand and cost management in Q4 2020. Kemira’s upgraded outlookKemira expects its operative EBITDA in H2 2020 to be above H1 2020 (H1 2020: EUR 214 million), and expects the full year 2020 operative EBITDA to increase from 2019 (2019: EUR 410 million). Previous outlook (published October 9, 2020)Kemira expects its operative EBITDA in H2 2020 to be below H1 2020 (H1 2020: EUR 214 million), but expects the full year 2020 operative

Optomed develops an IT system for the Finnish University Eye Clinics

Optomed Plc       Press Release      12 January 2021 at 9:00, Helsinki Optomed develops an IT system for the Finnish University Eye Clinics Optomed has been awarded a contract to develop an advanced IT system for the automation and evaluation of outcomes in ophthalmic care. The system is developed for the Finnish University Eye Clinics. Optomed was awarded the contract together with Carl Zeiss Oy through a public innovative procurement process. During the development phase, Optomed will create the system together with the Finnish University Eye Clinics. The development phase

Neles to publish its financial statements review for January-December 2020 on February 3, 2021

Neles Corporation, press release, January 12, 2021 at 09:00 a.m. EETNeles’ financial statements review for January-December 2020 will be published on Wednesday, February 3, 2021, approximately at 9:00 a.m. EET. A teleconference hosted by President and CEO Olli Isotalo and CFO Simo Sääskilahti will be held on the same day at 14:00 EET. To register as a participant for the teleconference and Q&A session, please dial in 5 to 10 minutes before the beginning of the event using the confirmation code and numbers below. The teleconference will be recorded and published on Neles’ website. The

Saga Pure ASA: Approval and publication of prospectus

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Oslo, 12 January 2021 Reference is made to the stock exchange notices from Saga Pure ASA (the "Company" or "Saga") on 20 October 2020, 30 November 2020, 14 December 2020, 21 December 2020 and 29 December 2020 regarding completed private placements of a total of 183,000,000 new

Correction of press release 2021-01-11 at 16.00 regarding order from Fortune 100 customer

Sivers Semiconductors AB issues a correction of press release 2021-01-11 at 16.00 regarding follow-up order from Fortune 100 customer.Sivers Photonics has been working with this key customer for approximately 28 months and not approximately 18 months as incorrectly stated. For more information please contact:Anders Storm, CEOTel: +46 70 262 6390E-mail: anders.storm@sivers-semiconductors.com Sivers Semiconductors is listed on Nasdaq First North Growth Market in Stockholm.The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se. Sivers

Rigshospitalet and Lundbeck announce partnership to find new ways to treat brain diseases

In a newly established partnership, researchers will examine how molecules enter the brain. The findings will be published as basic research, but in the long-run, the results may lead to improved treatment opportunities for brain diseases.H. Lundbeck A/S (Lundbeck), enters a partnership with the Department of Neurosurgery (Afdeling for Hjerne- og Nervekirurgi) at Rigshospitalet, which will provide new insights into how molecules enter the brain. The partnership gives researchers an opportunity to study fluids surrounding the brain to learn which compounds enter the brain and how they are

Employee share purchase program

Zalaris ASA has on 11 January completed the annual share purchase program for employees.As part of the program, Zalaris has sold 19,072 own shares to employees at a subscription price of NOK 40.18 per share. Following the sale Zalaris will hold 484,449 own shares. The shares will be transferred to the employees on or about 31 March 2021. The subscription price was based on the volume-weighted average share price in the period between 9 December to 30 December 2020, less 20% discount. To receive the discount the shares have a 12 months lock-up period. Please refer to the attached list (

Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy

Ascelia Pharma AB (publ) (ticker: ACE) today announced the clinical development plan for Oncoral. With Oncoral, Ascelia Pharma has the opportunity to develop a novel oral chemotherapy with the potential to offer both efficacy and safety benefits to cancer patients. The planned Phase 2 study, for the treatment of gastric cancer, is expected to start in H2 2021. Further details of the Oncoral development plan can be found on its dedicated website.Development plan – Phase 2 in gastric cancer With encouraging Phase 1 data, Ascelia Pharma has prepared the next steps of clinical development.

Kindred Group unaudited trading update for the fourth quarter 2020

· The Group’s strong business momentum continued throughout the fourth quarter of 2020, with active customers increasing by 11 per cent compared to the same period last year, and Gross winnings revenue reaching all-time high levels of approximately GBP 365 million. · Strong revenue growth combined with substantial operational leverage and continued focus on cost efficiency drove a significant annual increase in underlying EBITDA to approximately GBP 115 million.Kindred has delivered its strongest quarter ever with Gross winnings revenue at an all-time high of approximately GBP 365

Six logistics companies tested LBG-fueled trucks in Sweden with great results

Low-emission fuels are becoming increasingly popular in the Nordic transport sector. Six Swedish logistic companies that are part of MaserFrakt recently tested trucks that used liquefied biogas (LBG) as fuel. The companies’ expectations of significantly lower emissions and a better operating environment were exceeded.The transition to cleaner energy is accelerating in Sweden as the government is actively trying to reach national and EU emission goals. In the transport sector, the EU regulation on CO\2\ emission performance standards states that average CO\2\ emissions of new heavy-duty

Issue of a new green bond with a long maturity

During its MTN program, Kungsleden has issued a new green bond by SEK 300 million. The loan has a maturity of 6 years and was issued at the spread 1.5% over Stibor. At the same time, Kungsleden has repurchased short-term bonds with maturity as of September and October of the current year and bonds with maturity as of March 2022 for a total notional amount of SEK 187 million.During its MTN program, Kungsleden has issued a new green bond by SEK 300 million. The loan has a maturity of 6 years and was issued at the spread 1.5% over Stibor. At the same time, Kungsleden has repurchased short-term

BERGENBIO PRESENTING AT VIRTUAL INVESTOR CONFERENCES

Bergen, Norway, 12[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a member of the senior management team is presenting at the following virtual conferences: Solebury Trout Management Access Event, 6-15 January 2021 Register for the event here  Presentation available via platform 

Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant

- Medivir to Receive an Upfront Payment, as Well as Milestone Payments and Royalties- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid TumorsStockholm — Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences, Inc. (Nasdaq: IGMS), will receive global, exclusive development rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), leading to cell death (apoptosis) in tumor cells. The combination of IGM-

There are no items matching the current filter
There are no more items matching the current filter
Back to top